Sophiris Bio
La Jolla
About Sophiris Bio
Sophiris Bio is a biotech company that develops a treatment for the symptoms of benign prostatic hyperplasia. Their product includes topsalysin for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia and for the treatment of low- to intermediate-risk prostate cancer.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $47.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Sep 2017)
- Ticker: otcqb:SPHS
- Website: sophiris.com
- Phone: +1 858 777 1760
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Social Profiles
Canonical: https://fsome.com/organization/sophiris-bio-2232010 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.